ViroTact has developed an innovative molecular diagnostic test to show the presence of Covid-19. The technique enables quick, scalable and affordable point-of-care testing, which allows the number of tests in the Netherlands and worldwide to be scaled up. The technology is based on an existing patented platform technology for detecting proteases that are produced by viruses or bacteria. The test consists of an innovative substrate that emits near-infrared light in the presence of viral protease. This light is then captured and measured by a specially developed portable detector. Thanks to the detector, the test can be used as a practical point-of-care test that can be used by GPs, in emergency rooms or at the bedside of hospital patients. Other conceivable settings include airports and schools.
Carduso Capital participates in technology companies that are preferably based on the know-how represented in and originating from the Groningen science cluster in and around the University of Groningen (RUG) and the ...
These cookies make sure the website functions properly. These cookies also provide us to anonymously monitor website statistics. Because these cookies are essential for the website, you can not disable them without compromising the functionality of the website.
These cookies collect data that we use to understand how our website is used and perceived. These cookies also help us to optimize the website for the best user experience.
These cookies allow ad-networks to monitor your online behaviour so they can display relevant ads based on your interest and online behaviour. These cookies also prevent the same ads from being displayed over and over.